Form 10-Q Unicycive Therapeutics, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Noble Capital Reiterates Outperform Rating on Unicycive Therapeutics (UNCY)
May 14, 2024 8:44 AM EDTNoble Capital analyst Robert LeBoyer reiterated an Outperform rating and $6.00 price target on Unicycive Therapeutics (NASDAQ: UNCY).
The analyst comments "We Believe OLC Will Have Advantages Over Other Phosphate Binding Drugs.
OLC was formulated to reduce pill burden and improve compliance in... More
